Parenteral formulation of flavopiridol (NSC-649890)

R. Dannenfelser, Y. Surakitbanharn, S. E. Tabibi, Samuel H Yalkowsky

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Flavopiridol [5,7-dihydroxy-8-(4-N-methyl-2-hydroxypyridyl)-6'- chloroflavone hydrochloride] is a flavonoid with weak electrolyte properties and an intrinsic aqueous solubility of 0.024 mg/mL. Neither consolvency, complexation, nor pH control alone can produce an acceptable 10 mg/mL formulation that will not precipitate when diluted with blood. However, a combination of buffer and cyclodextrin or buffer and cosolvent can produce an acceptable 10 mg/mL formulation. In this paper, Flavopiridol is shown to be stable for at least one year in 30% hydroxypropyl β-cyclodextrin/0.1 M citrate buffer (4.52). This formulation does not precipitate for at least one hour upon dilution with Sorensen's phosphate buffer pH 7.4.

Original languageEnglish (US)
Pages (from-to)356-359
Number of pages4
JournalPDA Journal of Pharmaceutical Science and Technology
Volume50
Issue number6
StatePublished - 1996

Fingerprint

alvocidib
Buffers
Cyclodextrins
Flavonoids
Citric Acid
Solubility
Electrolytes
Phosphates

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Parenteral formulation of flavopiridol (NSC-649890). / Dannenfelser, R.; Surakitbanharn, Y.; Tabibi, S. E.; Yalkowsky, Samuel H.

In: PDA Journal of Pharmaceutical Science and Technology, Vol. 50, No. 6, 1996, p. 356-359.

Research output: Contribution to journalArticle

Dannenfelser, R, Surakitbanharn, Y, Tabibi, SE & Yalkowsky, SH 1996, 'Parenteral formulation of flavopiridol (NSC-649890)', PDA Journal of Pharmaceutical Science and Technology, vol. 50, no. 6, pp. 356-359.
Dannenfelser, R. ; Surakitbanharn, Y. ; Tabibi, S. E. ; Yalkowsky, Samuel H. / Parenteral formulation of flavopiridol (NSC-649890). In: PDA Journal of Pharmaceutical Science and Technology. 1996 ; Vol. 50, No. 6. pp. 356-359.
@article{198ed63b952b452cb54a58020fe1ed9f,
title = "Parenteral formulation of flavopiridol (NSC-649890)",
abstract = "Flavopiridol [5,7-dihydroxy-8-(4-N-methyl-2-hydroxypyridyl)-6'- chloroflavone hydrochloride] is a flavonoid with weak electrolyte properties and an intrinsic aqueous solubility of 0.024 mg/mL. Neither consolvency, complexation, nor pH control alone can produce an acceptable 10 mg/mL formulation that will not precipitate when diluted with blood. However, a combination of buffer and cyclodextrin or buffer and cosolvent can produce an acceptable 10 mg/mL formulation. In this paper, Flavopiridol is shown to be stable for at least one year in 30{\%} hydroxypropyl β-cyclodextrin/0.1 M citrate buffer (4.52). This formulation does not precipitate for at least one hour upon dilution with Sorensen's phosphate buffer pH 7.4.",
author = "R. Dannenfelser and Y. Surakitbanharn and Tabibi, {S. E.} and Yalkowsky, {Samuel H}",
year = "1996",
language = "English (US)",
volume = "50",
pages = "356--359",
journal = "PDA Journal of Pharmaceutical Science and Technology",
issn = "1079-7440",
publisher = "Parenteral Drug Association Inc.",
number = "6",

}

TY - JOUR

T1 - Parenteral formulation of flavopiridol (NSC-649890)

AU - Dannenfelser, R.

AU - Surakitbanharn, Y.

AU - Tabibi, S. E.

AU - Yalkowsky, Samuel H

PY - 1996

Y1 - 1996

N2 - Flavopiridol [5,7-dihydroxy-8-(4-N-methyl-2-hydroxypyridyl)-6'- chloroflavone hydrochloride] is a flavonoid with weak electrolyte properties and an intrinsic aqueous solubility of 0.024 mg/mL. Neither consolvency, complexation, nor pH control alone can produce an acceptable 10 mg/mL formulation that will not precipitate when diluted with blood. However, a combination of buffer and cyclodextrin or buffer and cosolvent can produce an acceptable 10 mg/mL formulation. In this paper, Flavopiridol is shown to be stable for at least one year in 30% hydroxypropyl β-cyclodextrin/0.1 M citrate buffer (4.52). This formulation does not precipitate for at least one hour upon dilution with Sorensen's phosphate buffer pH 7.4.

AB - Flavopiridol [5,7-dihydroxy-8-(4-N-methyl-2-hydroxypyridyl)-6'- chloroflavone hydrochloride] is a flavonoid with weak electrolyte properties and an intrinsic aqueous solubility of 0.024 mg/mL. Neither consolvency, complexation, nor pH control alone can produce an acceptable 10 mg/mL formulation that will not precipitate when diluted with blood. However, a combination of buffer and cyclodextrin or buffer and cosolvent can produce an acceptable 10 mg/mL formulation. In this paper, Flavopiridol is shown to be stable for at least one year in 30% hydroxypropyl β-cyclodextrin/0.1 M citrate buffer (4.52). This formulation does not precipitate for at least one hour upon dilution with Sorensen's phosphate buffer pH 7.4.

UR - http://www.scopus.com/inward/record.url?scp=0030483125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030483125&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 356

EP - 359

JO - PDA Journal of Pharmaceutical Science and Technology

JF - PDA Journal of Pharmaceutical Science and Technology

SN - 1079-7440

IS - 6

ER -